低危人乳头瘤病毒相关口咽鳞状细胞癌放化疗后的吞咽与沟通结局:TROG 12.01子研究
本子研究评估低危人乳头瘤病毒相关口咽鳞状细胞癌患者放化疗后的吞咽与沟通结局。126例接受70Gy放疗联合每周顺铂或西妥昔单抗的患者在治疗前、治疗后12和24个月行视频透视吞咽检查。顺铂组与西妥昔单抗组吞咽结局无差异,吞咽功能在12个月最差、24个月改善,各时间点误吸率低且吞咽功能高;高龄、较高T分期和舌根肿瘤(较扁桃体)与更差吞咽相关,言语和嗓音问题轻微。
要点
- 顺铂组与西妥昔单抗组在视频透视吞咽检查结局上无差异。
- 吞咽结局在治疗后12个月最差,至24个月改善,各时间点误吸率低且吞咽功能高。
- 高龄、较高T分期和舌根肿瘤(较扁桃体)与更差吞咽相关,言语和嗓音问题轻微。
核心结论
- 治疗后24个月吞咽安全有效,沟通高度可理解。
- 客观测量与患者报告测量对理解新治疗方式对吞咽相关结局的影响均重要。
研究设计与样本
- TROG 12.01子研究,纳入接受70Gy放疗联合每周顺铂或西妥昔单抗的低危人乳头瘤病毒相关口咽鳞状细胞癌患者。
- 126例患者接受视频透视吞咽检查,于治疗前、治疗后12和24个月进行,同时评估生活质量和症状严重程度。
主要发现
- 126例行视频透视吞咽检查的患者中,顺铂组与西妥昔单抗组吞咽结局无差异。
- 视频透视吞咽检查结局在12个月最差,24个月改善,各时间点误吸率低且吞咽功能高。
- 高龄、较高T分期和舌根肿瘤(较扁桃体)与更差吞咽相关。
- 临床医生和患者报告的言语和嗓音问题轻微。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This substudy aimed to assess swallow and communication outcomes in patients undergoing treatment for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. METHODS: Videofluoroscopy swallowing studies (VFSS) were conducted pre-treatment, 12 and 24 months post treatment, alongside quality of life and symptom severity measures for patients receiving 70Gy radiotherapy with either weekly cisplatin or cetuximab. RESULTS: Of 126 patients who underwent VFSS, there were no differences in swallowing outcomes between cisplatin and cetuximab arms. VFSS outcomes were worst at 12 months and improved by 24 months, with low aspiration rates and high swallow function at all timepoints. Older age, higher T-stage, and base of tongue tumors (versus tonsil) were associated with poorer swallowing. Clinician-and patient-reported speech and voice problems were minimal. CONCLUSIONS: Swallowing was safe and efficient, and communication highly intelligible at 24 months post treatment. Both 'objective' and patient-reported measures are important to understand the impact of new treatment approaches on swallowing-related outcomes.
引用
- Hughes R, Corry J, Rischin D, et al. Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01. Head Neck. 2025. PMID: 40662470. doi:10.1002/hed.28245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。